Anatara Lifesciences is pleased to advise a neutral cash flow for the quarter ending 31st March 2018 and an updated cash balance of $8.76 million as reported in the attached March Appendix 4C.
Anatara Chairman, Dr Mel Bridges said, "Since listing in October 2014, the Anatara team has worked diligently on delivering its key milestones, and is focused on continuing to do so. We are pleased to maintain a strong cash position and appreciate the patience of our shareholders whilst we positively move along the path to delivering shareholder value."
To view the full report, please visit:
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that aids in the control of diarrhoea and will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
Anatara Lifesciences Ltd